Abstract
Positron Emission Tomography (PET) can be used to assess changes of endogenous neurotransmitters induced by pharmacological or physiological challenges and has been successfully applied to the study of the dopaminergic system, and, to a lower extent, to the serotonergic, opioid and cholinergic systems. This review first introduces the principles underlying the assessment of fluctuations of endogenous neurotransmitters with PET and then summarizes the main results obtained for dopamine, with emphasis on clinical studies. The studies of serotonin, opioid peptides, acetylcholine and the few studies dealing with other neurotransmitters (GABA, glutamate) are subsequently reviewed. In conclusion the chances of successfully imaging endogenous neurotransmitters with PET as well as possible trends for the future are discussed.
Keywords: Binding potential (BP), competition model, endogenous neurotransmitter (EN), internalization model, pharmacological challenge, positron emission tomography (PET), serotonin, opioid peptides, acetylcholine, Parkinson's disease, amphetamine, epidepride, methylspiperone, fallypride, Antagonist Tracers
Current Psychopharmacology
Title: Imaging Endogenous Neurotransmitters In Vivo with Positron Emission Tomography Displacement Studies
Volume: 1
Author(s): Giampaolo Tomasi
Affiliation:
Keywords: Binding potential (BP), competition model, endogenous neurotransmitter (EN), internalization model, pharmacological challenge, positron emission tomography (PET), serotonin, opioid peptides, acetylcholine, Parkinson's disease, amphetamine, epidepride, methylspiperone, fallypride, Antagonist Tracers
Abstract: Positron Emission Tomography (PET) can be used to assess changes of endogenous neurotransmitters induced by pharmacological or physiological challenges and has been successfully applied to the study of the dopaminergic system, and, to a lower extent, to the serotonergic, opioid and cholinergic systems. This review first introduces the principles underlying the assessment of fluctuations of endogenous neurotransmitters with PET and then summarizes the main results obtained for dopamine, with emphasis on clinical studies. The studies of serotonin, opioid peptides, acetylcholine and the few studies dealing with other neurotransmitters (GABA, glutamate) are subsequently reviewed. In conclusion the chances of successfully imaging endogenous neurotransmitters with PET as well as possible trends for the future are discussed.
Export Options
About this article
Cite this article as:
Tomasi Giampaolo, Imaging Endogenous Neurotransmitters In Vivo with Positron Emission Tomography Displacement Studies, Current Psychopharmacology 2012; 1 (1) . https://dx.doi.org/10.2174/2211556011201010029
DOI https://dx.doi.org/10.2174/2211556011201010029 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibition of Cellular Proliferation by Drug Targeting of Cyclin-Dependent Kinases
Current Pharmaceutical Biotechnology PI3K-Akt Signaling and Viral Infection
Recent Patents on Biotechnology Mechanism of Anti-Tumor Effect by Curcumin in Hematological Malignancies
Current Pharmaceutical Analysis “Virostatics” as a Potential New Class of HIV Drugs
Current Pharmaceutical Design Current and Potential Anticancer Drugs Targeting Members of the UHRF1 Complex Including Epigenetic Modifiers
Recent Patents on Anti-Cancer Drug Discovery Advanced Glycation End Products (AGEs) and their Receptor (RAGE) System in Diabetic Retinopathy
Current Drug Discovery Technologies Modulation of Sirtuins: New Targets for Antiageing
Recent Patents on CNS Drug Discovery (Discontinued) From Small to Powerful: The Fragments Universe and its “Chem-Appeal”
Current Medicinal Chemistry Histone Methyltransferase Inhibitors: Novel Epigenetic Agents for Cancer Treatment
Current Medicinal Chemistry Recent Advances in Validating MDM2 as a Cancer Target
Anti-Cancer Agents in Medicinal Chemistry Molecular Pathways in the Progression of Hormone-Independent and Metastatic Prostate Cancer
Current Cancer Drug Targets Computational Analysis of Domains Vulnerable to HPV-16 E6 Oncoprotein and Corresponding Hot Spot Residues
Protein & Peptide Letters Tissue Transglutaminase Expression During Neural Differentiation of Human Mesenchymal Stem Cells
CNS & Neurological Disorders - Drug Targets Tobacco, Inflammation, and Respiratory Tract Cancer
Current Pharmaceutical Design Pulmonary Neuroendocrine Cell System in Health and Disease
Current Respiratory Medicine Reviews Gene Therapy in Plastic and Reconstructive Surgery
Current Gene Therapy Editorial [Hot Topic: Reprogramming of Normal and Cancer Stem Cells (Guest Editor: Pier Mario Biava)]
Current Pharmaceutical Biotechnology Selective Cytotoxic Effects of 5-Trifluoromethoxy-<i>1H</i>-indole-2,3-dione 3-Thiosemicarbazone Derivatives on Lymphoid-originated Cells
Anti-Cancer Agents in Medicinal Chemistry Cellular Senescence as a Target in Cancer Control
Current Cancer Therapy Reviews Therapeutic Potential of Natural Compounds in Lung Cancer
Current Medicinal Chemistry